AbbVie

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade AbbVie 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. 

CEO
Robert A. Michael
CEORobert A. Michael
Employees
55,000
Employees55,000
Headquarters
North Chicago, Illinois
HeadquartersNorth Chicago, Illinois
Founded
2011
Founded2011
Employees
55,000
Employees55,000

ABBV Key Statistics

Market cap
397.83B
Market cap397.83B
Price-Earnings ratio
171.81
Price-Earnings ratio171.81
Dividend yield
2.88%
Dividend yield2.88%
Average volume
6.26M
Average volume6.26M
High today
$229.49
High today$229.49
Low today
$223.98
Low today$223.98
Open price
$227.28
Open price$227.28
Volume
5.21M
Volume5.21M
52 Week high
$244.81
52 Week high$244.81
52 Week low
$164.39
52 Week low$164.39

Stock Snapshot

As of today, AbbVie(ABBV) shares are valued at $225.11. The company's market cap stands at 397.83B, with a P/E ratio of 171.81 and a dividend yield of 2.9%.

On 2025-12-01, AbbVie(ABBV) stock moved within a range of $223.98 to $229.49. With shares now at $225.11, the stock is trading +0.5% above its intraday low and -1.9% below the session's peak.

Trading volume for AbbVie(ABBV) stock has reached 5.21M, versus its average volume of 6.26M.

Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.

Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.

ABBV News

Nasdaq 1d
Guru Fundamental Report for ABBV

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model ba...

Guru Fundamental Report for ABBV
Simply Wall St 3d
Canadian Approval of SKYRIZI in Ulcerative Colitis Might Change the Case for Investing in AbbVie

In the past week, AbbVie announced that Canada's Drug Agency recommended reimbursement for SKYRIZI in ulcerative colitis and concluded pricing negotiations, exp...

Canadian Approval of SKYRIZI in Ulcerative Colitis Might Change the Case for Investing in AbbVie
Benzinga 3d
AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi

On Friday, AbbVie Inc. (NYSE:ABBV) announced two updates for ulcerative colitis patients in Canada. ABBV is in positive territory. Check the market position he...

AbbVie Scores Canadian Reimbursement Recommendations For Blockbuster Ulcerative Colitis Drug Skyrizi

Analyst ratings

68%

of 31 ratings
Buy
67.7%
Hold
29%
Sell
3.2%

More ABBV News

The Motley Fool 4d
REGENXBIO Q3 2025 Earnings Call Transcript

Image source: The Motley Fool. Thursday, November 6, 2025 at 4:16 p.m. ET Call participants President and CEO — Curran Simpson Chief Medical Officer — Steve Pa...

REGENXBIO Q3 2025 Earnings Call Transcript

People also own

Based on the portfolios of people who own ABBV. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.